Bausch + Lomb has concluded its acquisition of a portion of the assets and intellectual property for Miochol(R)-E from affiliates of Novartis AG. The business intends to complete the acquisition of the remaining assets and intellectual property upon the necessary regulatory clearance.
Bausch + Lomb has concluded its acquisition of a portion of the assets and intellectual property for Miochol-E from affiliates of Novartis AG. The business intends to complete the acquisition of the remaining assets and intellectual property upon the necessary regulatory clearance. It intends to complete full purchase of the Miochol-E assets and intellectual property existing within the EEA upon approval from the European Commission.
Miochol-E adds further diversity to our extensive ophthalmic pharmaceuticals portfolio. We're glad patients will continue to benefit from this broadly known product, said Brent L. Saunders, chief executive officer, Bausch + Lomb.
Miochol-E is an injectable miotic pharmaceutical used during certain eye surgeries to constrict the pupil. Miotics are most commonly used in cataract surgery to stabilize the iris fluids inside the eye when small tears occur in the capsule of the lens. In most markets worldwide there are only two injectable miotics products available, of which Miochol-E is one.
Miochol-E has been widely used by ophthalmic surgeons for nearly 20 years. Adding this trusted product to Bausch + Lomb's quality eye health product line is a perfect fit for B+L and its patients, says Dr David Ritterband, clinical associate professor of ophthalmology, The New York Eye and Ear Infirmary and New York Medical College.
Under the agreement, Bausch + Lomb will be provided technical assistance by Novartis to assist in the transfer of Miochol-E manufacturing. The companies have not disclosed more detailed purchase terms.
AAO 2024: Detail outlined for Artificial Intelligence Innovation Center at Wilmer Eye Institute
October 24th 2024During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.